Gammal Hassanien, DO
Internal Medicine · Paterson, NJNPI 1528262961
Payments from drug & device makers
Across 232 payments — averaging $43.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Madrigal Pharmaceuticals$1K
- AbbVie$849
- Novo Nordisk$797
- Amgen$723
- Bayer$526
- plus $4K from 30 others
What the payments were for
- Food & beverage$9,86898%
- Education$1752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $1,498 |
| Madrigal Pharmaceuticals | 24 | $1,329 |
| AbbVie(2 entities) | 13 | $849 |
| Novo Nordisk | 13 | $797 |
| Amgen(2 entities) | 23 | $723 |
| Bayer | 16 | $526 |
| Exact Sciences | 3 | $372 |
| Gilead | 11 | $372 |
| Bard Peripheral Vascular, Inc. | 3 | $345 |
| Mannkind Corporation | 18 | $337 |
| Corcept Therapeutics | 4 | $296 |
| Amarin Pharma, Inc. | 21 | $286 |
| Abiomed | 3 | $274 |
| Braeburn Inc. | 2 | $241 |
| GSK | 9 | $231 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $203 |
| Abbott | 2 | $179 |
| Biotronik Inc. | 1 | $150 |
| Angiodynamics, Inc. | 2 | $129 |
| Ironwood Pharmaceuticals, Inc | 1 | $124 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $123 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $113 |
| Boehringer Ingelheim | 7 | $100 |
| Astellas Pharma US Inc | 1 | $95 |
| Qiagen, LLC | 1 | $86 |
| Dexcom, Inc. | 3 | $65 |
| Mylan Specialty L.p. | 2 | $33 |
| Cumberland Pharmaceuticals, Inc. | 1 | $33 |
| Pfizer | 1 | $20 |
| Insulet Corporation | 1 | $20 |
| G Medical Diagnostic Services, Inc. | 1 | $19 |
| Biocryst US Sales Co., LLC | 1 | $16 |
| Intra-sana Laboratories | 1 | $16 |
| Merck | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$1,095
- Creon$495
- RYBELSUS$462
- Cologuard Collection Kit$372
- BREZTRI$370
- AIRSUPRA$369
- Korlym$268
- Repatha$250
- Epclusa$250
- LINZESS$248
- Kerendia$248
- Ozempic$247
- LOKELMA$245
- BRIXADI$241
- FREESTYLE LIBRE 3$158
- Crosser iQ$143
- Impella$132
- Lutonix Drug Coated Balloon$125
- Mavyret$125
- Vascepa$125
How this compares
$10,043 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 105 | $77,468 |
| JanumetSitagliptin Phos/Metformin Hcl | 98 | $76,659 |
| OzempicSemaglutide | 54 | $68,780 |
| JanuviaSitagliptin Phosphate | 81 | $67,110 |
| EliquisApixaban | 75 | $42,139 |
| JardianceEmpagliflozin | 46 | $39,676 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $36,634 |
| XifaxanRifaximin | 12 | $35,964 |
| LinzessLinaclotide | 40 | $27,969 |
| Dihydroergotamine Mesylate | 14 | $26,973 |
| Zileuton ErZileuton | 15 | $26,352 |
| KerendiaFinerenone | 25 | $24,247 |
| EntrestoSacubitril/Valsartan | 24 | $20,668 |
| TradjentaLinagliptin | 26 | $20,640 |
| Amcinonide | 12 | $20,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia | $15 | $143,769179 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $1,498 | $126,002196 claims |
| Novo NordiskOzempic | $797 | $68,78054 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $100 | $66,49385 claims |
| PfizerEliquis | $20 | $42,13975 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $203 | $35,96412 claims |
| AbbVieLinzess | $849 | $27,96940 claims |
| BayerKerendia | $526 | $24,24725 claims |
| GSKBreo Ellipta | $231 | $15,38733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Paterson
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.